Your browser doesn't support javascript.
loading
High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators.
Homsher, Michelle F; Beshore, Douglas C; Cassaday, Jason; Squadroni, Brian; Mohammed, Elizabeth; Hartnett, Michelle; Day, Stephen; Ma, Lei; Pechter, David; Smith, Michelle D; Monsma, Fredrick; Zuck, Paul; Finley, Michael F; Uebele, Victor N; Hermes, Jeffrey D.
Afiliación
  • Homsher MF; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Beshore DC; 2 Discovery Chemistry, Merck Research Labs, West Point, PA, USA.
  • Cassaday J; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Squadroni B; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Mohammed E; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Hartnett M; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Day S; 3 MRL Pipeline Support, Merck and Co, Montreal, Canada.
  • Ma L; 4 Neuroscience, Merck Research Labs, West Point, PA, USA.
  • Pechter D; 5 Assay Operations, Merck Research Labs, Kenilworth, NJ, USA.
  • Smith MD; 6 In Vitro Pharmacology, Merck and Co, Kenilworth, NJ, USA.
  • Monsma F; 6 In Vitro Pharmacology, Merck and Co, Kenilworth, NJ, USA.
  • Zuck P; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Finley MF; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Uebele VN; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
  • Hermes JD; 1 Screening and Protein Sciences, Merck and Co, North Wales, PA, USA.
SLAS Discov ; 22(8): 1060-1066, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28426939
ABSTRACT
Agonist shift assays feature cross-titrations of allosteric modulators and orthosteric ligands. Information generated in agonist shift assays can include a modulator's effect on the orthosteric agonist's potency (alpha) and efficacy (beta), as well as direct agonist activity of the allosteric ligand (tauB) and the intrinsic binding affinity of the modulator to the unoccupied receptor (KB). Because of the heavy resource demand and complex data handling, these allosteric parameters are determined infrequently during the course of a drug discovery program and on a relatively small subset of compounds. Automation of agonist shift assays enables this data-rich analysis to evaluate a larger number of compounds, offering the potential to differentiate compound classes earlier and prospectively prioritize based on desired molecular pharmacology. A high-throughput calcium-imaging agonist shift assay was pursued to determine the allosteric parameters of over 1000 positive allosteric modulator (PAM) molecules for the human muscarinic acetylcholine receptor 1 (M1). Control compounds were run repeatedly to demonstrate internal consistency. Comparisons between potency measurements and the allosteric parameter results demonstrate that these different types of measurements do not necessarily correlate, highlighting the importance of fully characterizing and understanding the allosteric properties of leads.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor Muscarínico M1 / Ensayos Analíticos de Alto Rendimiento Límite: Animals Idioma: En Revista: SLAS Discov Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor Muscarínico M1 / Ensayos Analíticos de Alto Rendimiento Límite: Animals Idioma: En Revista: SLAS Discov Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos